Presentation of Data on Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Loco-regional Pancreatic Tumors

Aim: A dose escalation study of Gemcitabine for treatment of
unresectable pancreatic cancer, using a targeted intra-arterial
delivery catheter (RenovoCath™).

Methods: 20 patients at two centers were enrolled with a fourstage
dose escalation of gemcitabine up to 1000 mg/m2.
Enzyme markers, blood count, and constitutional endpoints
were monitored to assess for dose-limiting toxicities. Feasibility
and safety of repeated intra-arterial treatment sessions were
assessed. Secondary endpoints included the effect on tumor
size by imaging, tumor markers, and conversion to resectability.

Results: Data for 20 patients enrolled is presented. Efficacy
analysis was limited to the 15 patients who received more than
two treatments.

SUMMARY: Intra-arterial delivery of gemcitabine using localized delivery catheter, RenovoCath, is safe provided:

  • Patients with prior biliary stent/drain receive peri-op antibiotics
  • IR training/support is necessary to avoid guide mediated vascular complications
  • Early efficacy results of survival is encouraging, especially in patients with prior radiation where there may exist a synergistic effect with localized trans-arterial delivery of gemcitabine

View the full presentation (pdf)

Previous Post
RenovoRx Announces FDA Clearance for Expanded Labeling
Next Post
Researchers Report Survival Benefits with Use of RenovoCath™ in Patients with Locally Advanced Pancreatic Tumors